Skip to main content

Table 6 Background of patients stratified by dialysis treatment (peritoneal dialysis or hemodialysis) after matching

From: Survival and predictive factors in dialysis patients with COVID-19 in Japan: a nationwide cohort study

 

Hemodialysis

Peritoneal dialysis

p valuea

n

%

n

%

Age

 < 60

36

48.0

12

48.0

1.000

 60 s

21

28.0

7

28.0

 

 ≥ 70

18

24.0

6

24.0

 

Gender

 Male

55

73.3

20

80.0

0.601

 Female

20

26.7

5

20.0

 

Primary disease

 Chronic glomerulonephritis

15

21.1

8

36.4

0.507

 Diabetes mellitus

36

50.7

8

36.4

 

 Nephrosclerosis

6

8.5

2

9.1

 

 Others

14

19.7

4

18.2

 

Duration of dialysis

 < 1 year

10

13.7

6

24.0

0.032

 1 to < 5 years

24

32.9

14

56.0

 

 5 to < 10 years

22

30.1

5

20.0

 

 10 to < 15 years

9

12.3

0

0.0

 

 ≥ 15 years

8

11.0

0

0.0

 

Complication

 Hypertension

  No

41

54.7

12

50.0

0.815

  Yes

34

45.3

12

50.0

 

 Diabetes mellitus

  No

36

48.0

16

66.7

0.159

  Yes

39

52.0

8

33.3

 

 Cardiovascular disease

  No

51

69.9

21

87.5

0.110

  Yes

22

30.1

3

12.5

 

 Chronic respiratory disease

  No

67

91.8

24

100.0

0.331

  Yes

6

8.2

0

0.0

 

 Peripheral arterial disease

  No

64

87.7

23

95.8

0.443

  Yes

9

12.3

1

4.2

 

 Malignancy

  No

65

90.3

23

95.8

0.675

  Yes

7

9.7

1

4.2

 

 Number of complications

  0

12

16.0

6

25.0

0.164

  1

25

33.3

11

45.8

 

  ≥ 2

38

50.7

7

29.2

 

Oxygenation

 No

12

16.0

4

16.0

1.000

 Yes

54

72.0

18

72.0

 

 Ventilator or ECMO

9

12.0

3

12.0

 

Remdesivir

 No

63

87.5

23

95.8

0.443

 Yes

9

12.5

1

4.2

 

Dexamethasone

 No

27

37.5

11

45.8

0.481

 Yes

45

62.5

13

54.2

 
  1. aFisher’s exact test